Get started
Author

Yasmin Nabil Laimon

Observed names: Laimon, Yasmin Nabil, Y. Laimon, Y.N. Laimon, YN Laimon, Yasmin L. Nabil, Yasmin Laimon, Yasmin N Laimon, Yasmin N. Laimon, Yasmin Nabil . Laimon, Yasmin Nabil. Laimon
ORCID: 0000-0003-0848-9843
Observed ORCIDs: 0000-0003-0848-9843, 0000-0002-2646-7894
OpenAlex ID: A5089546439
KDM6A epigenetically regulates subtype plasticity in small cell lung cancer
2023 · Leslie Duplaquet, Yixiang Li, et al. · Nature Cell Biology · 73
PDF
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
2024 · Yufei Wang, Alicia Buck, et al. · Molecular Cancer · 60
PDF
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
2022 · Hsiao-Yun Chen, Yavuz T. Durmaz, et al. · Nature Communications · 46
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
2025 · Tejas Jammihal, Renee Maria Saliby, et al. · Nature Cancer · 37
PDF
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
2023 · Thomas Denize, Opeyemi A. Jegede, et al. · Clinical Cancer Research · 36
PDF
Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma
2024 · Talal El Zarif, Karl Semaan, et al. · Cell Reports · 29
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma
2025 · Jiao Li, Kaimeng Huang, et al. · Nature Metabolism · 22
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
2025 · Shilpa Singh, Catherine E. Gleason, et al. · Nature · 21
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer
2025 · Deli Hong, Ying Lyu, et al. · Developmental Cell · 3
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
2024 · Shilpa Singh, Catherine E. Gleason, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.
2024 · Yasmin Nabil Laimon, Morgan Paul, et al. · Journal of Clinical Oncology · 3
PDF
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al. · Clinical Cancer Research · 2
PDF
2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial
2025 · B. Simsek, S.M. Niman, et al. · Annals of Oncology · 2
EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation
2025 · Yixiang Li, Yasmin N. Laimon, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial
2025 · Yasmin Laimon, Morgan Paul, et al. · Laboratory Investigation · 2
Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)
2023 · Karl Semaan, Talal El Zarif, et al. · Cancer Research · 2
The Role of the Pathologist in Renal Cell Carcinoma Management
2023 · Sayed Matar, Nourhan El Ahmar, et al. · Hematology/Oncology Clinics of North America · 2
Giant angiolipoma of the back complicated with ulceration and sepsis: unusual presentation of a rare benign tumour
2019 · AH Elfallal, YN Laimon, et al. · Annals of The Royal College of Surgeons of England · 2
PDF
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
2026 · Prathyusha Konda, Alexandra J. Wakolbinger, et al. · Nature Communications · 1
PDF
Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer
2026 · Damien Vasseur, Shin Saito, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Abstract A003: Baseline levels of HIF2 target proteins and response to the HIF2α inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma
2025 · Gabriel Roberti. de Oliveira, Berkay Simsek, et al. · Molecular Cancer Therapeutics · 1
Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.
2025 · Yasmin Nabil Laimon, Nourhan El Ahmar, et al. · Journal of Clinical Oncology · 1
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
2025 · Renee Maria Saliby, Chris Labaki, et al. · Journal of Clinical Oncology · 1
Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.
2024 · Eddy Saad, Chris Labaki, et al. · Journal of Clinical Oncology · 1
PDF
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.
2024 · Nourhan El Ahmar, Sayed Matar, et al. · Journal of Clinical Oncology · 1
Works count: 86
Citation count: 354
H-index: 8
I10-index: 8
Year
Topic
Type